Tonix Pharmaceuticals Holding Corp. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Tonmya at $11.0 million, 81% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
29
|
14
|
7
|
5
|
3
|
2
|
2
|
3
|
3
|
| Tonmya |
—
|
11
share 80.9%
|
4
share 54.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Zembrace Symtouch |
—
|
2
+27.1%
share 14.7%
|
3
+44.6%
share 42.6%
|
3
+26.1%
share 58.2%
|
3
+3.9%
share 78.5%
|
2
share 78.6%
|
2
share 83.4%
|
2
share 96.3%
|
2
share 88.1%
|
| Tosymra |
—
|
1
+38.8%
share 4.4%
|
0
-46.2%
share 3.2%
|
1
+776.8%
share 15.5%
|
1
+110.1%
share 21.5%
|
0
share 21.4%
|
0
share 16.6%
|
0
share 3.7%
|
0
share 11.9%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1430306
- Former names
- TAMANDARE EXPLORATIONS INC. (until Oct 17, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.